Breaking News

CMAB Receives Positive Opinion Following External Quality Audit

CDMO’s fully integrated facility in Suzhou, China was found to conform to EU Eudralex Vol. 4 GMP guidelines

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CMAB Biopharma (Suzhou) Inc., a pure-play contract development and manufacturing organization (CDMO) specializing in the production of mammalian cell-derived biologic products, received a positive opinion in an external European quality audit conducted by Parexel International Co.   The purpose of the audit was to confirm that CMAB’s quality standards are in line with European GMP, thereby verifying that its quality assurance and control systems can meet the requirements of development, pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters